Epsmon, reducing the risk of sudden death in epilepsy.
Measurable patient outcomesCraig led the full development of Epsmon for SUDEP Action, concept through clinical deployment. The product demonstrated a measurable reduction in the risk of sudden unexpected death in epilepsy. All IP was released to the charity on completion.
BMJ AwardsHSJ WinnerSUDEP International